THYROID TUMORS : HISTOLOGICAL CLASSIFICATION AND GENETIC FACTORS INVOLVED IN THE DEVELOPMENT OF THYROID CANCER

Classification of thyroid tumours and their variants is described with special respect to some recent findings on somatic mutations characteristics which are associated with individual types of malignity. Special attention is paid to the interrelations between thyroid nodules and malignity and predictive risk factors are listed.

[1]  P. Chappuis,et al.  Increased risk for nonmedullary thyroid cancer in the first degree relatives of prevalent cases of nonmedullary thyroid cancer: a hospital-based study. , 2001, The Journal of clinical endocrinology and metabolism.

[2]  E. Paal,et al.  A clinicopathologic study of minimally invasive follicular carcinoma of the thyroid gland with a review of the English literature , 2001, Cancer.

[3]  Yuri E Nikiforov,et al.  High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. , 2003, Cancer research.

[4]  A. Tessitore,et al.  A novel case of multiple endocrine neoplasia type 2A associated with two de novo mutations of the RET protooncogene. , 1999, The Journal of clinical endocrinology and metabolism.

[5]  C. Key,et al.  Prognostic factors for thyroid carcinoma , 1997, Cancer.

[6]  C. Eng,et al.  Risk and penetrance of primary hyperparathyroidism in multiple endocrine neoplasia type 2A families with mutations at codon 634 of the RET proto-oncogene. Groupe D'etude des Tumeurs à Calcitonine. , 1998, The Journal of clinical endocrinology and metabolism.

[7]  S. Pilotti,et al.  Minimally invasive (encapsulated) follicular carcinoma of the thyroid gland is the low-risk counterpart of widely invasive follicular carcinoma but not of insular carcinoma , 2002, Virchows Archiv.

[8]  P. Goodfellow,et al.  Novel germline RET proto-oncogene mutations associated with medullary thyroid carcinoma (MTC): mutation analysis in Japanese patients with MTC , 1997, Oncogene.

[9]  R. Kloos,et al.  Current Approaches to Primary Therapy for Papillary and Follicular Thyroid Cancer , 2001 .

[10]  S. Sherman.  Anaplastic carcinoma clinical aspects , 2006 .

[11]  al. et,et al.  Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B , 1995, Science.

[12]  B. Ponder,et al.  Germline mutation of RET codon 883 in two cases of de novo MEN 2B , 1997, Oncogene.

[13]  H. Gharib,et al.  Medullary thyroid carcinoma in multiple endocrine neoplasia types 2A and 2B. , 1994, Surgery.

[14]  M. Schlumberger,et al.  RET mutations in exons 13 and 14 of FMTC patients. , 1995, Oncogene.

[15]  H. Wolfe,et al.  Familial medullary thyroid carcinoma and C cell hyperplasia. , 1981, Clinics in endocrinology and metabolism.

[16]  L. Mulligan,et al.  Germline dinucleotide mutation in codon 883 of the RET proto-oncogene in multiple endocrine neoplasia type 2B without codon 918 mutation. , 1997, The Journal of clinical endocrinology and metabolism.

[17]  D. Dean,et al.  Prognostic indicators in differentiated thyroid carcinoma. , 2000, Cancer control : journal of the Moffitt Cancer Center.

[18]  O. Alsanea.  Familial nonmedullary thyroid cancer , 2000, Current treatment options in oncology.

[19]  G. Brabant,et al.  Duplication of 9 base pairs in the critical cysteine‐rich domain of the RET proto‐oncogene causes multiple endocrine neoplasia type 2A , 1998, Human mutation.

[20]  L. Quadro,et al.  A GTG to ATG novel point mutation at codon 804 in exon 14 of the RET proto‐oncogene in two families affected by familial medullary thyroid carcinoma , 1998, Human mutation.

[21]  H. Goepfert,et al.  Changing concepts in the pathogenesis and management of thyroid carcinoma , 1996, CA: a cancer journal for clinicians.

[22]  M. Ringel,et al.  Unusual types of thyroid neoplasms. , 1996, Endocrinology and metabolism clinics of North America.

[23]  C. Malchoff,et al.  The genetics of hereditary nonmedullary thyroid carcinoma. , 2002, The Journal of clinical endocrinology and metabolism.

[24]  B. Ponder,et al.  Genotype‐phenotype correlation in multiple endocrine neoplasia type 2: report of the International RET Mutation Consortium , 1995, Journal of internal medicine.

[25]  G. Lenoir,et al.  Oncogenic activation of RET by two distinct FMTC mutations affecting the tyrosine kinase domain , 1997, Oncogene.

[26]  D E Goldgar,et al.  Localization of a susceptibility gene for familial nonmedullary thyroid carcinoma to chromosome 2q21. , 2001, American journal of human genetics.

[27]  John P. Bilezikian,et al.  CONSENSUS: Guidelines for Diagnosis and Therapy of MEN Type 1 and Type 2 , 2001 .

[28]  A. Miyauchi,et al.  Two Germline Missense Mutations at Codons 804 and 806 of the RET Proto‐oncogene in the Same Allele in a Patient with Multiple Endocrine Neoplasia Type 2B without Codon 918 Mutation , 1999, Japanese journal of cancer research : Gann.

[29]  P. Goodfellow,et al.  Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[30]  F. Raue,et al.  A new hot spot for mutations in the ret protooncogene causing familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2A. , 1998, The Journal of clinical endocrinology and metabolism.

[31]  R. Hofstra,et al.  A novel point mutation in the intracellular domain of the ret protooncogene in a family with medullary thyroid carcinoma. , 1997, The Journal of clinical endocrinology and metabolism.

[32]  C Eng,et al.  The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. , 1996, JAMA.

[33]  B. Corvilain.  The natural history of thyroid autonomy and hot nodules. , 2003, Annales d'endocrinologie.

[34]  Andrzej Bartke,et al.  The Endocrine System , 1998, Alcohol health and research world.

[35]  J. Breza,et al.  Novel germline mutation in the transmembrane region of RET gene close to Cys634Ser mutation associated with MEN 2A syndrome , 2005, Journal of Molecular Medicine.

[36]  J. Figge.  Epidemiology of Thyroid Cancer , 2006 .

[37]  W. Böcker,et al.  Prognostic factors in medullary thyroid carcinomas. Survival in relation to age, sex, stage, histology, immunocytochemistry, and DNA content , 1988, Cancer.

[38]  J. Köhrle,et al.  Thyroid hormone receptors and type I iodothyronine 5'-deiodinase activity of human thyroid toxic adenomas and benign cold nodules. , 2002, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[39]  D. Nostrand,et al.  Thyroid cancer : a comprehensive guide to clinical management , 2000 .

[40]  W. Höppner,et al.  A duplication of 12 bp in the critical cysteine rich domain of the RET proto-oncogene results in a distinct phenotype of multiple endocrine neoplasia type 2A. , 1997, Human molecular genetics.

[41]  G. Sheline,et al.  TUMORS OF THE THYROID AND PARATHYROID GLAND. , 1964, California medicine.